Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Onge, Minister of Canadian Heritage, announced the appointment of Cheryl Hickman as the next chairperson of the Canada Council for the Arts for a five-year term. Ms. Hickman currently serves as a ...

Ontario's financial services regulator, FSRA, has revoked the life insurance and accident & sickness insurance agent licence of Daniel Lath (Lath) and imposed two administrative penalties in the total ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, ...

A packed audience at Sydney’s International Convention Centre for a UIA Gala event last night, heard Rachel Goldberg and Jon ...

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their ...